6-K filed Sep 8, 2026 at 06:51 ET
Pharvaris announced overwhelmingly positive topline data from the CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks. The study met its primary endpoint with an 83% attack rate reduction versus placebo (p<0.0001) and all secondary endpoints were met with statistical significance, with a well-tolerated safety profile. This data supports planned NDA submissions starting in the first half of 2027, positioning deucrictibant as a potential first-in-class oral therapy with injectable-like efficacy for both on-demand and prophylactic treatment, which is a transformative event for this late-stage biotech company.